SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Piramal Pharma Ltd

BSE: 543635 NSE: PPLPHARMA ISIN: INE0DK501011
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Piramal Pharma Ltd belong to?
Piramal Pharma Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Piramal Pharma Ltd a good quality company?
Piramal Pharma Ltd is a weak quality company, based on a inconsistent 10 year financial track record.
Q.3 Is Piramal Pharma Ltd undervalued or overvalued?
Piramal Pharma Ltd appears Fair, as its key valuation ratios are in line with their past averages.
Q.4 Is Piramal Pharma Ltd a good buy now?
Piramal Pharma Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Piramal Pharma Ltd?
Piramal Pharma Ltd revenue growth is 20.4% for FY-2025 , which is above its 5 year CAGR of 0% , indicating faster growth.
Q.2 Gross Profit margin of Piramal Pharma Ltd?
Piramal Pharma Ltd Gross profit margin which is the profit after deduction of direct costs, is 20.8% for FY-2025 , which is above its 5 year median of 19% , indicating increasing margins.
Q.3 Operating Profit Margin of Piramal Pharma Ltd?
Piramal Pharma Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 19.17% for FY-2025 , which is above its 5 year median of 14.26% indicating increasing margins.
Q.4 Net Profit Margin of Piramal Pharma Ltd?
Piramal Pharma Ltd Net Profit Margin is 13.08% for FY-2025 , is above with its 5 year median of 11%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 20.8 19
Operating Profit Margin 19.17 14.26
Net Profit Margin 13.08 11
Q.5 Return on Asset of Piramal Pharma Ltd?
Piramal Pharma Ltd Return on Asset is 6.64%, which is above its 5 year historical median of 5.47%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Piramal Pharma Ltd?
Piramal Pharma Ltd Return on equity is 9.83% for FY-2025 , which is above its historical median of 7.97%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Piramal Pharma Ltd?
Piramal Pharma Ltd Return on capital employed is 12.4% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 11.25%, indicating value creation.
Q.8 Cash conversion cycle of Piramal Pharma Ltd?
Piramal Pharma Ltd Cash conversion cycle is 75 days, above its historical median of 72 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.52 0.51
ROE 9.83 7.97
ROCE 12.4 9.86
Cash Conversion Cycle 75 days 72 days
Q.9 Debt to Equity ratio of Piramal Pharma Ltd?
Piramal Pharma Ltd Debt-to-Equity ratio is 0.17 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Piramal Pharma Ltd?
Piramal Pharma Ltd Debt to cash flow from operations is 2.23 , which is at a moderate level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Piramal Pharma Ltd?
Promoters hold 34.86% of the Piramal Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Piramal Pharma Ltd vs industry peers?
Piramal Pharma Ltd revenue CAGR is 0.00% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 5,285.7 137.1
Gross Profit 1,099.5 15.1
Operating Profit 1,009 16
Net Profit 691 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.52 0.8
ROE 9.83 8.91
ROCE 12.4 11.59
Cash Conversion Cycle (days) 75.23 76

Valuation & price assessment

Q.1 Stock return of Piramal Pharma Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of 28.74% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - 28.7% -32.4%
Q.3 Valuation ratios of Piramal Pharma Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 27.39 113.89 40.28
Price to Book 2.49 2.84 2.77
Price to Sales 3.93 4.65 2.65
EV to EBITDA 15.88 35.00 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×